PubMed for id: 380989

Year	Number of Results
2001	2
2002	1
2009	1
2011	2
2014	2
2015	1
2016	1
2017	4
2018	3
2024	0

1

The role of histone lysine methyltransferase NSD3 in cancer.

Han X, Piao L, Zhuang Q, Yuan X, Liu Z, He X. Han X, et al. Onco Targets Ther. 2018 Jul 5;11:3847-3852. doi: 10.2147/OTT.S166006. eCollection 2018. Onco Targets Ther. 2018. PMID: 30013365 Free PMC article. Review.

2

The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck.

Saloura V, Vougiouklakis T, Sievers C, Burkitt K, Nakamura Y, Hager G, van Waes C. Saloura V, et al. Oral Oncol. 2018 Jun;81:100-108. doi: 10.1016/j.oraloncology.2018.04.014. Epub 2018 May 3. Oral Oncol. 2018. PMID: 29884408 Free PMC article. Review.

3

Identification of a peptide inhibitor for the histone methyltransferase WHSC1.

Morrison MJ, Boriack-Sjodin PA, Swinger KK, Wigle TJ, Sadalge D, Kuntz KW, Scott MP, Janzen WP, Chesworth R, Duncan KW, Harvey DM, Lampe JW, Mitchell LH, Copeland RA. Morrison MJ, et al. PLoS One. 2018 May 9;13(5):e0197082. doi: 10.1371/journal.pone.0197082. eCollection 2018. PLoS One. 2018. PMID: 29742153 Free PMC article.

4

NSD3 keeps IRF3 active.

Mino T, Takeuchi O. Mino T, et al. J Exp Med. 2017 Dec 4;214(12):3475-3476. doi: 10.1084/jem.20171980. Epub 2017 Nov 20. J Exp Med. 2017. PMID: 29158375 Free PMC article.

5

The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3.

Wang C, Wang Q, Xu X, Xie B, Zhao Y, Li N, Cao X. Wang C, et al. J Exp Med. 2017 Dec 4;214(12):3597-3610. doi: 10.1084/jem.20170856. Epub 2017 Nov 3. J Exp Med. 2017. PMID: 29101251 Free PMC article.

6

Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.

Liu Z, Piao L, Zhuang M, Qiu X, Xu X, Zhang D, Liu M, Ren D. Liu Z, et al. Oncol Rep. 2017 Nov;38(5):2796-2802. doi: 10.3892/or.2017.5936. Epub 2017 Sep 4. Oncol Rep. 2017. PMID: 28901481 Free PMC article.

7

Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.

Jones DH, Lin DI. Jones DH, et al. Mol Clin Oncol. 2017 Aug;7(2):301-307. doi: 10.3892/mco.2017.1289. Epub 2017 Jun 8. Mol Clin Oncol. 2017. PMID: 28781807 Free PMC article.

8

Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4.

Zhang Q, Zeng L, Shen C, Ju Y, Konuma T, Zhao C, Vakoc CR, Zhou MM. Zhang Q, et al. Structure. 2016 Jul 6;24(7):1201-8. doi: 10.1016/j.str.2016.04.019. Epub 2016 Jun 9. Structure. 2016. PMID: 27291650 Free PMC article.

9

NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue.

Suzuki S, Kurabe N, Ohnishi I, Yasuda K, Aoshima Y, Naito M, Tanioka F, Sugimura H. Suzuki S, et al. Pathol Res Pract. 2015 May;211(5):404-8. doi: 10.1016/j.prp.2014.10.013. Epub 2014 Nov 13. Pathol Res Pract. 2015. PMID: 25466466

10

NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.

French CA, Rahman S, Walsh EM, Kühnle S, Grayson AR, Lemieux ME, Grunfeld N, Rubin BP, Antonescu CR, Zhang S, Venkatramani R, Dal Cin P, Howley PM. French CA, et al. Cancer Discov. 2014 Aug;4(8):928-41. doi: 10.1158/2159-8290.CD-14-0014. Epub 2014 May 29. Cancer Discov. 2014. PMID: 24875858 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

16 results

Results by year